Tirzepatide

Tirzepatide is a dual GIP/GLP-1 receptor agonist that reduces appetite and slows gastric emptying while enhancing insulin sensitivity. It is FDA-approved as Mounjaro for type 2 diabetes and Zepbound for obesity, and produced 22.5% weight loss in the SURMOUNT trials.

Tirzepatide is a synthetic once-weekly injectable peptide developed by Eli Lilly that simultaneously activates two incretin hormone receptors — the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. This dual-agonist mechanism distinguishes it from every GLP-1-only agent on the market and is responsible for the substantially greater weight loss and glycemic improvements observed in clinical trials.

Approved by the FDA in May 2022 as Mounjaro for adults with type 2 diabetes, and in November 2023 as Zepbound for adults with obesity or overweight with at least one weight-related comorbidity, tirzepatide became the fastest-growing medication in either indication within a year of launch. Its brand-name cost without insurance exceeds $1,000 per month in the United States, and prior authorization requirements rose sharply to approximately 84% of commercial plans by late 2024 — reflecting both the high demand and insurer caution around the drug class.

Structurally, tirzepatide is a 39-amino-acid acylated peptide bearing a C20 fatty diacid moiety that enables albumin binding, extending the half-life to approximately five days and supporting once-weekly subcutaneous administration. The peptide's native sequence was engineered to show high affinity and full agonism at the GIP receptor while displaying a functional bias at the GLP-1 receptor toward cyclic AMP (cAMP) generation over β-arrestin recruitment — a design choice thought to contribute to superior tolerability compared with older GLP-1 agonists.

Beyond diabetes and obesity, tirzepatide is under active investigation for obstructive sleep apnea, metabolic dysfunction-associated steatohepatitis (MASH), heart failure with preserved ejection fraction, and polycystic ovary syndrome. The ongoing SURMOUNT-MMO outcomes trial is testing whether tirzepatide can reduce hard cardiovascular morbidity and mortality endpoints in people with obesity but without type 2 diabetes, a population previously unstudied in major outcomes trials.

Tirzepatide's clinical effects arise from the coordinated activation of two distinct G-protein-coupled receptors: the GIP receptor (GIPR) and the GLP-1 receptor (GLP-1R). Both receptors are expressed in the pancreatic beta cell, where their simultaneous stimulation produces additive and potentially synergistic increases in glucose-dependent insulin secretion. Tirzepatide is specifically designed to act as an imbalanced agonist — it engages the GIPR with affinity and signaling characteristics similar to native GIP while acting as a biased partial agonist at the GLP-1R, preferentially coupling to the Gs/cAMP pathway rather than the β-arrestin pathway (Coskun et al., JCI Insight 2020).

At the GLP-1 receptor, tirzepatide reproduces the effects of native GLP-1: it slows gastric emptying (reducing post-meal glucose excursions), suppresses glucagon secretion in a glucose-dependent manner, and acts on hypothalamic and brainstem appetite-regulating circuits to reduce food intake and promote satiety. These central effects are mediated in part through direct action on area postrema and nucleus tractus solitarius neurons and in part through vagal afferent signaling from the gut.

At the GIP receptor, tirzepatide exerts several metabolically distinct actions. In adipose tissue, GIPR agonism cooperates with insulin to enhance glucose uptake, augment glycerol synthesis, and increase lipid clearance in the fed state, while in the fasted state it promotes lipolysis and free fatty acid release. This context-dependent regulation of adipocyte metabolism may contribute to tirzepatide's ability to reduce fat mass beyond what weight loss alone would predict. In skeletal muscle and liver, GIPR activation appears to independently improve insulin sensitivity through mechanisms still under investigation — a 2025 post-hoc analysis of SURMOUNT-1 found that tirzepatide's improvements in insulin sensitivity exceeded what could be explained by weight reduction alone, implying direct receptor-mediated effects on metabolic tissue.

The dual-receptor mechanism also modifies the central appetitive response. GIP receptors are expressed in the ventromedial hypothalamus and other appetite-regulating nuclei, and rodent studies demonstrate that central GIPR activation reduces energy intake in a manner additive to GLP-1R activation. This brain-gut synergy likely accounts for a portion of the superior weight loss observed with tirzepatide compared to GLP-1-only agonists in head-to-head trials.

Tirzepatide has been evaluated in one of the largest clinical development programs in metabolic medicine, spanning the five-study SURPASS program (type 2 diabetes) and the ongoing SURMOUNT program (obesity and related conditions). Taken together, these trials enrolled tens of thousands of participants and have generated a body of evidence that consistently positions tirzepatide as the most effective pharmacological agent for weight reduction in human history.

**SURPASS program (type 2 diabetes).** In SURPASS-1 (Lancet, 2021; n=478, 40 weeks, monotherapy), all three tirzepatide doses reduced HbA1c by –1.87% to –2.07% vs +0.04% for placebo. Up to 92% of participants reached the ADA target of HbA1c < 7%, and up to 52% reached normoglycemic HbA1c < 5.7%. In SURPASS-2 (NEJM, 2021; n=1,879, 40 weeks), tirzepatide 15 mg reduced HbA1c by –2.30% and body weight by –11.2 kg, both significantly superior to semaglutide 1.0 mg (–1.86% HbA1c; –5.7 kg weight). The SURPASS-CVOT trial (2024; n > 12,000, median 4-year follow-up) demonstrated cardiovascular non-inferiority of tirzepatide vs dulaglutide in patients with type 2 diabetes and established atherosclerotic cardiovascular disease: the primary MACE endpoint occurred in 12.2% of tirzepatide patients vs 13.1% of dulaglutide patients, with a 47% greater body-weight reduction in the tirzepatide arm (–11.6% vs –4.5%).

**SURMOUNT-1 (NEJM, 2022; n=2,539, 72 weeks).** This pivotal trial enrolled adults with obesity without diabetes. Mean body weight reductions were –16.0% at 5 mg, –21.4% at 10 mg, and –22.5% at 15 mg, compared with –2.4% for placebo. These results represent the largest weight-loss magnitude ever recorded for a pharmaceutical agent in a phase 3 randomized trial. A 2025 post-hoc analysis of this same trial showed that among the 1,032 participants with prediabetes at baseline, tirzepatide reduced the rate of progression to type 2 diabetes to near-zero during the treatment period, with regression to normoglycemia observed in the majority, and that over 60% of the glycemic improvement was attributable to mechanisms other than weight loss alone.

**SURMOUNT-5 (2025).** This was the first head-to-head phase 3 randomized trial directly comparing tirzepatide with semaglutide 2.4 mg (the FDA-approved weight management dose). Over 72 weeks, tirzepatide produced a least-squares mean weight change of –20.2% versus –13.7% for semaglutide — a difference of approximately 6.5 percentage points, confirming the superiority signal first seen in SURPASS-2 in a pure-obesity population.

**SURMOUNT-OSA (Nature Medicine, 2025).** Two parallel 52-week phase 3 trials demonstrated that tirzepatide 15 mg significantly reduced the apnea-hypopnea index in adults with moderate-to-severe obstructive sleep apnea and obesity (–27.4 events/hour in CPAP users; –25.3 events/hour in non-CPAP users), accompanied by reductions in hypoxic burden and improvements in patient-reported sleep quality. This data supported an FDA indication expansion. A cardiovascular benefit mediation analysis suggested the sleep apnea improvements could independently contribute to MACE risk reduction beyond the weight loss effect alone.[1][2][3][4][5]

Peptides commonly paired with Tirzepatide for synergistic effects.